An interventional study of Nurse Case Management and standard diabetologist care in Type 2 Diabetes, sponsored by BCDiabetes.Ca. Completed at 1 site in Canada. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2016-01-27.
Sponsored by BCDiabetes.Ca · Not applicable, Interventional, and Treatment
Among 756 studies in Diabetes Mellitus, Type 2 with a site in Canada — 82 open to participants now, 112 under way, 25 of them phase 3. Diabetes Mellitus, Type 2 · Canada.
Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Canada, this one is the 399th largest by enrollment of the 673 interventional ones that give a count, is one of 41 that started in 2012, is one of 204 with no phase, and was the 309th registered.
10,378 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,410 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →82 of the 756 studies in Diabetes Mellitus, Type 2 with a site in Canada are open now. Recruiting first, the newest first:
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18–80
Amgen · Sites in Canada, United States
Ages 18+
May Faraj, PDt, PhD · Sites in Canada
Ages 40–70 · Healthy volunteers
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
Boehringer Ingelheim · Sites in Canada, United States, Australia and 2 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 203 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
756 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 122 · Phase 3 267 · Phase 4 66
First in 1999; this study’s year is marked. 41 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 80 across 8,356 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 227 across the 673 interventional studies, 300 across the 82 observational. Of the 594 that completed or were terminated, 272 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
412 of 756 have an industry lead sponsor. The 10 most frequent:
BCDiabetes.Ca is the lead sponsor of 4 studies on the registry; none are open to participants now.
BCDiabetes.Ca has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
38 of the studies in Diabetes Mellitus, Type 2 with a site in Canada that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059377Phase 3Ottawa Heart Institute Research CorporationSemaglutide for Smoking Cessation in Patients With Diabetes | 2026-12 |
| NCT05427084Phase 3Ottawa Heart Institute Research CorporationCanagliflozin Targeting Vascular Inflammation | 2026-12 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT05776420Phase 3Unity Health TorontoEffect of a Healthy Food Voucher on Blood Glucose Control in People With Type 2 Diabetes or Prediabetes | 2027-04-01 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
Add all 38 to your calendar (.ics) → With an account.
Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will examine whether patients with diabetes who are either 1) newly discharged from hospital or 2) referred to an endocrinologist for management will have better diabetes outcomes when their care is managed primarily by a dedicated case manager (intervention) than by an endocrinologist (standard care) after 6 months of treatment.
The study will be a randomized-control trial recruiting patients with type 2 diabetes in a specialty care setting from two sources:
Patients who meet the inclusion criteria will be randomly assigned into either the NCM group or SC group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
nurse case management of diabetic variables
Behavioral: Nurse Case Management
standard diabetologist care
Behavioral: standard diabetologist care
routine care by diabetologist \& team
A1c
changes in A1C between NCM vs. SC
Time frame: 6 months
diabetes distress (DDS)
changes in diabetes distress between NCM vs. SC. Diabetes Distress (DDS) will be assessed using the 17-item Diabetes Distress Scale (DDS) developed by Polonsky and colleagues. The DDS measures emotional distress and functioning as it relates to living with diabetes. Responses are scored on a 6-point Likert scale (1=no problem to 6=serious problem). A total score is derived by taking the mean of all items. A score of \< 2 indicate low/no distress, 2 - 2.9 indicates moderate distress, and score of ≥ 3 indicates high distress.
Time frame: 6 months
blood pressure
changes in BP between NCM vs. SC. Blood pressure will be measured using an Omron Digital Blood Pressure Monitor HEM-907. Two upper arm readings are taken with the average of the two recorded.
Time frame: 6 months
BMI
changes in BMI between NCM vs. SC. Height and weight will be measured using the Healthometer mechanical eye level upright standard physician scale with attached stadiometer. Body mass index (BMI) are calculated as weight in kilograms divided by height in meters squared.
Time frame: 6 months
Self-management behaviours
changes in behaviour habits between NCM vs. SC. Self-management behaviours will be assessed using items from the Summary of Diabetes Self-Care Activities Measure-revised (SDSCA-R).This instrument measures self-care behaviors including diet, exercise, blood sugar testing and foot care. Participants are asked to report the number of days in the past week (range 0-7 days) in which he/she performed specific self-care practices. Greater number of days indicates better self-management.
Time frame: 6 months
Medication adherence
changes in medication adherence between NCM vs. SC. Medication adherence will be assessed using the 4-item Moriskyscale that assesses beliefs and behaviors associated with taking medications.Responses are scored on a dichotomous scale: 0=no and 1=yes. A total score is calculated by adding up all items with lower scored indicating better adherence.
Time frame: 6 months
Patient motivation
change in patient motivation between NCM vs. SC. motivation will be measured by the 13-item Patient Activation Measure which assesses participants' self-reported knowledge, skills, and confidence an individual has when managing his/her own health.
Time frame: 6 months
Diabetes-specific Social Support
change in diabetes-specific social support between NCM vs. SC Diabetes-specific Social Support will be assessed with a 4-item scale developed by Tang et al. that measures amount of support and satisfaction with support from family, friends and the health care team.
Time frame: 6 months
Depressive Symptoms Severity
change in depressive symptoms between NCM vs. SC Depressive Symptom Severity will be assessed using the 9-item PRIME-MD Patient Health Questionnaire (PHQ-9)
Time frame: 6 months
The record gives a start of Aug 2012, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BCDiabetes.Ca